Therapeutic efficacy and dose-limiting toxicity of auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: Evaluation of (125)I- vs. (131)I-labeled CO17-1A in a human colorectal cancer model Journal Article


Authors: Behr, T. M.; Sgouros, G.; Vougioukas, V.; Memtsoudis, S.; Gratz, S.; Schmidberger, H.; Blumenthal, R. D.; Goldenberg, D. M.; Becker, W.
Article Title: Therapeutic efficacy and dose-limiting toxicity of auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: Evaluation of (125)I- vs. (131)I-labeled CO17-1A in a human colorectal cancer model
Abstract: Recent clinical results suggest that higher anti-tumor efficacy may be achieved with internalizing monoclonal antibodies (MAbs) at lower toxicity when labeled with Auger-electron, as compared to conventional β-emitters. The aim of our study was to compare the toxicity and anti-tumor efficacy of the 125I-labeled internalizing MAb, CO17-1A, with its 131I-labeled form in a human colon cancer model in nude mice. Biodistribution studies were performed in nude mice bearing s.c. human colon cancer xenografts. For therapy, the mice were injected either with unlabeled 125I- or 131I- labeled CO17-1A at equitoxic doses. Control groups were left untreated, were given a radiolabeled isotype-matched irrelevant antibody or a tumor- specific, but noninternalizing antibody. The maximum tolerated activities (MTD) of 131I-and 125I-CO17-1A without artificial support were 300 μCi and 3 mCi, respectively. Myelotoxicity was dose-limiting; bone marrow transplantation allowed for an increase of the MTD to 400 μCi of 131I- 17-1A, whereas the MTD of 125I-17-1A with bone marrow support had not been reached at 5 mCi. Whereas no significant therapeutic effects were seen with unlabeled CO17-1A, tumor growth was retarded with 131I-CO17-1A. With the 125I-label, however, therapeutic results were clearly superior. In contrast, no significant difference was observed in the therapeutic efficacy of the 131I- vs. 125I-labeled, noninternalizing antibodies. Our data indicate a superiority of Auger-electron emitters, such as 125I, as compared to therapy with conventional β-emitters with internalizing antibodies. The lower toxicity of Auger emitters may be due to the short path length of their low-energy electrons, which can reach the nuclear DNA only if the antibody is internalized (as is the case in antigen-expressing tumor tissue, but not in the stem cells of the red marrow).
Keywords: controlled study; drug efficacy; nonhuman; sensitivity and specificity; colorectal cancer; mouse; animals; mice; animal experiment; animal model; tumor cells, cultured; dose-response relationship, radiation; colorectal neoplasms; antibodies, monoclonal; isotope labeling; tissue distribution; iodine radioisotopes; mice, nude; transplantation, heterologous; neoplasm transplantation; radioimmunotherapy; bone marrow transplantation; electrons; internalization; bone marrow toxicity; cancer transplantation; beta rays; immunotoxins; auger electron spectroscopy; humans; human; female; priority journal; article; monoclonal antibody i 131; monoclonal antibody i 125
Journal Title: International Journal of Cancer
Volume: 76
Issue: 5
ISSN: 0020-7136
Publisher: John Wiley & Sons  
Date Published: 1998-05-29
Start Page: 738
End Page: 748
Language: English
DOI: 10.1002/(sici)1097-0215(19980529)76:5<738::aid-ijc20>3.0.co;2-z
PUBMED: 9610734
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 12 December 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. George Sgouros
    146 Sgouros